Rafferty Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Rafferty Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Buy	+2,427	New	+$195K	﹤0.01%	1108
2026 Q1	–	Sell	-2,851	Closed	-$225K	–	1064
2025 Q4	$225K	Buy	2,851 +632	+28%	+$54.7K	﹤0.01%	1068
2025 Q3	$203K	Buy	+2,219	New	+$181K	﹤0.01%	1071
2025 Q1	–	Sell	-3,622	Closed	-$200K	–	1064
2024 Q4	$200K	Buy	+3,622	New	+$208K	﹤0.01%	1107
2019 Q3	–	Sell	-10,614	Closed	-$872K	–	803
2019 Q2	$872K	Buy	+10,614	New	+$755K	0.02%	584

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's ANIP Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 2,427 shares worth $201K. The stake represents ﹤0.01% of the portfolio and ranks #1108 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in ANIP as recently as Q4 2025.

Rafferty Asset Management first reported a position in ANIP in Q2 2019 and has held it in 5 quarters since. The position peaked at $872K in Q2 2019. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Rafferty Asset Management held 2,427 shares of ANI Pharmaceuticals worth $201K as of Q2 2026.
ANI Pharmaceuticals was a new Rafferty Asset Management position in Q2 2026.
ANI Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1108 holding.
Rafferty Asset Management first reported a position in ANI Pharmaceuticals in Q2 2019 and has held it in 5 quarters since.
Rafferty Asset Management's ANI Pharmaceuticals position peaked at $872K in Q2 2019.
308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.